Therapy-related B-cell acute lymphoblastic leukemia (B-ALL), a rare form of acute lymphoblastic leukemia (ALL), may develop in patients receiving cytotoxic treatments for a prior malignancy, according ...

Aug. 21, 2024 — An international team of scientists has uncovered a mechanism by which acute myeloid leukemia (AML) cells sustain their growth. AML cells prevent the synthesis of proteins that ...

Previously reported MRD negative CR in 2 of 3 relapsed/refractory AML patients enrolled in first dose level and schedule of Phase 1 clinical ...

for the treatment of relapsed/refractory hematologic malignancies including acute myeloid leukemia ("AML"). As announced in December 2024, three AML patients had been treated at the lowest dose ...

Previously reported MRD negative CR in 2 of 3 relapsed/refractory AML patients enrolled in first dose level and schedule of Phase 1 clinical trial of SENTI-202 maintaining remission - - Strengthened ...

Shorla currently markets two products, Nelarabine for the treatment of T-cell leukemia and JYLAMVO for the treatment of acute lymphoblastic ... phase CML or blast crisis than in patients with ...

DLL3 targeting Radio-DARPin MP0712 to enter first-in-human study in 2025, pending regulatory clearanceStrategic partnership with Orano Med on ...

A 42-year-old hypertensive and diabetic male presented to the hospital with complaints of severe weakness, decreased appetite and loss of weight for three months. He also developed difficulty of ...

The FDA has granted AUTX-703, a first-in-class oral KAT2A/B degrader, fast track designation for the treatment of relapsed/refractory acute myelogenous leukemia ... a significant increase in ...